JPMorgan Chase & Co. boosted its stake in shares of Repro Med Systems, Inc. (NASDAQ:KRMD) by 175.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,599 shares of the company’s stock after purchasing an additional 14,400 shares during the period. JPMorgan Chase & Co.’s holdings in Repro Med Systems were worth $162,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Two Sigma Advisers LP purchased a new position in Repro Med Systems during the second quarter worth approximately $152,000. Bank of America Corp DE purchased a new position in shares of Repro Med Systems in the 2nd quarter valued at $360,000. Jane Street Group LLC purchased a new position in shares of Repro Med Systems in the 2nd quarter valued at $323,000. Swiss National Bank purchased a new position in shares of Repro Med Systems in the 2nd quarter valued at $517,000. Finally, Bank of New York Mellon Corp purchased a new stake in Repro Med Systems during the 2nd quarter worth $702,000. 66.52% of the stock is currently owned by institutional investors.
In other news, Chairman R John Fletcher bought 21,052 shares of the company’s stock in a transaction dated Monday, November 30th. The shares were acquired at an average cost of $4.48 per share, with a total value of $94,312.96. Following the completion of the transaction, the chairman now directly owns 50,050 shares in the company, valued at approximately $224,224. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph M. Jr. Manko bought 10,000 shares of the company’s stock in a transaction dated Wednesday, December 16th. The stock was purchased at an average cost of $5.70 per share, for a total transaction of $57,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 53,552 shares of company stock worth $263,923 over the last quarter. Insiders own 39.00% of the company’s stock.
KRMD stock opened at $6.02 on Friday. Repro Med Systems, Inc. has a 52 week low of $3.60 and a 52 week high of $12.84. The company has a market capitalization of $264.54 million, a price-to-earnings ratio of -602.00 and a beta of 0.16. The firm’s 50-day moving average is $5.27 and its two-hundred day moving average is $7.40.
Repro Med Systems (NASDAQ:KRMD) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). Repro Med Systems had a positive return on equity of 6.79% and a negative net margin of 1.74%. The company had revenue of $6.08 million for the quarter, compared to the consensus estimate of $7.21 million. As a group, sell-side analysts anticipate that Repro Med Systems, Inc. will post 0.06 EPS for the current year.
Repro Med Systems Profile
Repro Med Systems, Inc, doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing.
See Also: Analyst Ratings Trading
Want to see what other hedge funds are holding KRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repro Med Systems, Inc. (NASDAQ:KRMD).
Receive News & Ratings for Repro Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.